Targovax 
TRVX a clinical phase norwegian Biotech is currently at market cap NOK 327 million / 35 million USD.
Value inflection point very close as the company will need to raise funds in the very near future, which must either come from investors or from a possible partner deal.
PRESENTATION OF ONCOS-102 MELANOMA DATA AT SITC ANNUAL MEETING
https://www.healthcap.eu/presentation-of-oncos-102-melanoma-data-at-sitc-annual-meeting/
Q3 report:
https://www.targovax.com/en/event/q3-2019-targovax-quarterly-results/
Q3 transcript:
https://finance.yahoo.com/news/edited-transcript-trvx-ol-earnings-204325101.html
TRVX a clinical phase norwegian Biotech is currently at market cap NOK 327 million / 35 million USD.Value inflection point very close as the company will need to raise funds in the very near future, which must either come from investors or from a possible partner deal.
PRESENTATION OF ONCOS-102 MELANOMA DATA AT SITC ANNUAL MEETING
https://www.healthcap.eu/presentation-of-oncos-102-melanoma-data-at-sitc-annual-meeting/
Q3 report:
https://www.targovax.com/en/event/q3-2019-targovax-quarterly-results/
Q3 transcript:
https://finance.yahoo.com/news/edited-transcript-trvx-ol-earnings-204325101.html
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.